索西替尼 T3620
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
10 mg | 1206163-45-2 | ¥893.00 | 询底价 |
50 mg | 1206163-45-2 | ¥1,870.00 | 询底价 |
1 mg | 1206163-45-2 | ¥285.00 | 询底价 |
5 mg | 1206163-45-2 | ¥672.00 | 询底价 |
2 mg | 1206163-45-2 | ¥397.00 | 询底价 |
500 mg | 1206163-45-2 | ¥6,860.00 | 询底价 |
100 mg | 1206163-45-2 | ¥2,970.00 | 询底价 |
200 mg | 1206163-45-2 | ¥4,380.00 | 询底价 |
1 mL | 1206163-45-2 | ¥739.00 | 询底价 |
25 mg | 1206163-45-2 | ¥1,390.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Solcitinib
描述: Solcitinib (GLPG-0778) 是一种可口服的,选择性的竞争性JAK1抑制剂,IC50值为 9.8 nM,可用于银屑病的研究。它对其选择性是对 JAK2、JAK3 和 TYK2 的 11、55 和 23 倍。
激酶实验: In vitro HotSpotSM kinase profiling of 289 kinases is performed. The assay is conducted in the presence of 10 μM [33P]-ATP, using brigatinib concentrations ranging from 0.05 nM to 1 μM.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 20 mg/mL(51.4 mM)
关键字: GLPG0778 | Solcitinib | Janus kinase | GLPG 0778 | Inhibitor | GSK 2586184 | inhibit | JAK | GSK2586184
相关产品: JAK-IN-21 | Jaspamycin | WDR5-IN-6 | Avitinib | JAK1-IN-4 | AG490 | Ruxolitinib phosphate | JAK1-IN-8 | Dehydrocrenatidine | 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
相关库: JAK-STAT Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Bioactive Compound Library
索西替尼 T3620信息由TargetMol中国为您提供,如您想了解更多关于索西替尼 T3620报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途